AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ovid Therapeutics Inc. (OVID)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.57

-0.02 (-2.60%)

At close: Feb 20, 2025, 3:59 PM

0.57

-1.17%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	0.56
Market Cap	40.74M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.46
PE Ratio (ttm)	-1.25
Forward PE	n/a
Analyst	Buy

Ask	0.6
Volume	334,403
Avg. Volume (20D)	369,884
Open	0.62
Previous Close	0.59
Day's Range	0.56 - 0.62
52-Week Range	0.56 - 3.79
Beta	undefined

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 5, 2017

Employees 25

Stock Exchange NASDAQ

Ticker Symbol OVID

Website https://www.ovidrx.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for OVID stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 422.92% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Ovid Therapeutics Inc. is scheduled to release its earnings on Mar 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

8 months ago

-76%

Ovid Therapeutics shares are trading lower after T... Unlock content with Pro Subscription

News

3 months ago · zacks.com

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.